"Biota has worked with the CDCO since its inception. We consider the timely generation of high-quality physicochemical, metabolic and pharmacokinetic data at an early stage to be a key factor in successful drug discovery. The CDCO has consistently provided such services to a high professional standard consistent with pharmaceutical drug discovery needs and expectations. The CDCO's ability to provide local access to world class expertise and advice in "our" time zone is particularly valued." – Dr Alistair Draffan, Director, Drug Discovery, Biota, Melbourne, Australia
"Cancer Therapeutics CRC (CTx) highly values its relationship with CDCO and this is reflected by our long standing partnership. CDCO's expertise in drug candidate optimisation is critical for guiding decision making in our projects and to this end results are always delivered in a professional and timely manner. Key for us is the collaboration model which allows flexibility and fit with our drug discovery and development projects. We particularly value the interaction with CDCO personnel in our project meetings, an interaction which ultimately benefits our understanding and provides rapid input into the design of the next iteration of molecules. We have now been working with the CDCO for over 6 years and, pending the successful outcome of our extension bid, we are looking forward to working with them for many more."
– Dr. Ian Street, CSO, Cancer Therapeutics CRC, Melbourne, Australia
"The Drug Discovery group in the Schools of Biomedical Sciences and Pharmacy have worked collaboratively with the CDCO to provide high quality ADME support for a Wellcome Trust-funded cardiovascular drug development project. Over the past four years, we have been impressed by the consistent delivery of high quality data, and its meaningful interpretation and recommendations, provided by CDCO. Furthermore, CDCO have demonstrated their flexibility to adapt protocols and to establish new methods to address our specific needs. The relationship we have built is one of committed involvement and partnership. We fully intend to continue our relationship with CDCO for the current project and in the future."
– Prof Peter Fischer, Chair in Medicinal Chemistry, University of Nottingham, Nottingham, UK
"Bionomics has worked with CDCO on a number of our discovery programs. We have found CDCO to be a professional, high quality partner in drug discovery. One feature that sets CDCO apart from other providers in the ADME-PK space is the relationship established between CDCO study managers and our program leaders. The study managers are always responsive and well-informed. They provide guidance on study design and interpretation of results in the context of the whole project. This approach to plan for the right data at the right time has helped us to achieve our project milestones."
– Dr. Andrew Harvey, Vice President Drug Discovery, Bionomics Limited, Adelaide, Australia
"CDCO was instrumental for the progression of DNDi projects and is a key partner in the "LO AUS" Consortium that led to the generation of 2 potential candidates for Chagas disease...not only are the data generated of high quality and within timelines, but also their interpretation a great value. CDCO in that sense is a real partner for us. Its pro-active and flexible attitude, as well as the discussion and generation of ideas and proposal of potential studies for further progression of projects is a real "added value". Project management is efficient and reports are such that we can include them directly into regulatory documentation. We would therefore recommend without hesitation CDCO to other groups."
– Dr. Eric Chatelain, Head of Drug Discovery, Drugs for Neglected Diseases Initiative (DNDi), Geneva, Switzerland